You are correct up to a point. Nanoviricides is most certainly a developing versus production bio nano-pharm. Nanoviricides is two years from product-generated revenue. (Licensing revenue is another story and not one easily predicted.) But...Outbreaks do generate interest and do in turn have an inflationary impact on PPS. The threat of pandemic outbreak and resulting impacts on economies speeds the regulatory pipeline and can influence grant and orphan funding for endemic illnesses with potential geo creep or pandemic mutability. Nanoviricides and others in the anti viral research space do not exist in a vacuum. Events in the real world impact the potential value of developing technologies. Hype is an intangible that has made millionaires.
Really, it is strange how few people here get that simple fact. An outbreak of flu in China right now is simply of no relevance to NNVC. China could come begging for a cure and NNVC won't have one to sell.
I think you miss the . NNVC will not sell the cure, but might be allowed to "test" the cure.